FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
MDxHealth SA (Euronext: MDXH.BR), announced today that it has signed a distribution agreement with Teva Pharmaceuticals to offer its SelectMDx(TM) for Prostate Cancer test to Teva's urology customers throughout Israel. read more
SuperBIO is an innovation project supported through the EU Horizon2020 funding programme. The € 3.8 million project supports the development of promising industrial value chains in the bioeconomy. It therefore engages with the EU bio-based business community. The project provides 10 different types of innovation services to third party SMEs which are funded by the project for 75%. As such, it brings these value chains closer to reality. The SuperBIO consortium includes four industrial cluster organisations (from Belgium, France, Spain and Poland), and six service providers (from the UK, Germany and Belgium). read more
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it will report its half-year 2016 results and outlook for the remainder of the year on 6 September 2016 at 07:00h CEST. read more
Encouraging positive safety and efficacy results across Phase II studies. Transition to allogeneic strategy for osteoporosis read more
Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announced in its press release of 23 August 2016 that it prepares for a significant external funding before year end to which the main shareholder will contribute along with potential other investors. read more
Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces its unaudited financial results for the six months ended June 30, 2016, which have been prepared in accordance with the IAS 34 “Interim Financial Reporting” as adopted by the European Union. read more
• Successful Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers • Phase 2 study in first auto-immune indication planned to start by year-end • Cash position strengthened by $40M upfront payment from AbbVie and €30M private placement read more
Progressing innovative development pipeline with 4 compounds targeting novel treatments for diabetic eye disease OASIS Phase IIIb 2 year follow up study confirms long term safety and efficacy of ocriplasmin - publication in Ophthalmology AAO Journal read more
Propanc Health Group Corporation (OTCQB: PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company executed a contract manufacturing agreement with AmatsiQBiologicals, based in Gent, Belgium. The agreement covers the development and GMP (Good Manufacturing Practice) production of certain enzymes for development purposes, including but not limited to first-in-man studies for the Company’s lead product, PRP. read more
Management to Host Conference Call at 2pm CEST/8am EDT Today read more